Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res (Q42211579)
Jump to navigation
Jump to search
scientific article published on 5 June 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res |
scientific article published on 5 June 2014 |
Statements
1 reference
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res (English)
1 reference
1 reference
Joseph Gathe
1 reference
Ramin Ebrahimi
1 reference
Gilles Pialoux
1 reference
Giovanni Di Perri
1 reference
Jacques Reynes
1 reference
Thai Nguyen
1 reference
Kirsten White
1 reference
David Piontkowsky
1 reference
5 June 2014
1 reference
1 reference
14
1 reference
7
1 reference
581-589
1 reference
Identifiers
1 reference
1 reference